Avantor, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 14, 2024 at 06:00 am EST
Share
Avantor, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 6,967.2 million compared to USD 7,512.4 million a year ago. Net income was USD 321.1 million compared to USD 686.5 million a year ago.
Basic earnings per share from continuing operations was USD 0.48 compared to USD 1.02 a year ago. Diluted earnings per share from continuing operations was USD 0.47 compared to USD 1.01 a year ago.
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies & applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
AVANTOR, INC. 
